

Association of the Autoimmune Disease Scleroderma w Cancer

Science

343, 152-157

DOI: [10.1126/science.1246886](https://doi.org/10.1126/science.1246886)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Potential "Core" of Vitamin D Receptor and Vitamin D Hypothesis: Synthesis of Common Basis of Some Autoimmune Diseases and Associated Cancers via Autophagy. Cloning & Transgenesis, 2013, 03, .	0.1	0
2	Tumor Immunotherapy: Lessons from Autoimmunity. Frontiers in Immunology, 2014, 5, 212.	2.2	18
3	Does the Immune System Naturally Protect Against Cancer?. Frontiers in Immunology, 2014, 5, 197.	2.2	183
4	Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy. Frontiers in Immunology, 2014, 5, 176.	2.2	35
5	Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nature Communications, 2014, 5, 5797.	5.8	120
6	Presymptomatic autoantibodies in Sjögren's syndrome: what significance do they hold for the clinic?. Expert Review of Clinical Immunology, 2014, 10, 815-817.	1.3	4
7	Cancer mutation tied to scleroderma. Cancer, 2014, 120, 1289-1289.	2.0	0
9	Raynaud's Phenomenon, Inflammatory Arthritis, and Weight Loss: Pay Attention to the Man Behind the Curtain. Arthritis Care and Research, 2014, 66, 1263-1268.	1.5	1
10	Scleroderma. Current Opinion in Rheumatology, 2014, 26, 646-652.	2.0	59
11	Update on scleroderma-associated interstitial lung disease. Current Opinion in Rheumatology, 2014, 26, 630-636.	2.0	20
12	New autoantibody detection technologies yield novel insights into autoimmune disease. Current Opinion in Rheumatology, 2014, 26, 717-723.	2.0	13
13	Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis. Journal of Clinical & Cellular Immunology, 2014, 05, 212.	1.5	14
14	The Autoimmune Myopathies. , 2014, , 547-554.		1
15	Systemic sclerosis: beyond limited and diffuse subsets?. Nature Reviews Rheumatology, 2014, 10, 200-202.	3.5	31
16	Can Cancer Trigger Autoimmunity?. Science, 2014, 343, 147-148.	6.0	11
19	The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nature Reviews Rheumatology, 2014, 10, 671-681.	3.5	113
20	Treating cardiovascular risk in RA requires multidisciplinary care. Nature Reviews Rheumatology, 2014, 10, 202-204.	3.5	6
21	Molecular and cellular basis of scleroderma. Journal of Molecular Medicine, 2014, 92, 913-924.	1.7	35

#	ARTICLE	IF	CITATIONS
22	Association of Hashimoto's thyroiditis with thyroid cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 845-852.	1.6	61
23	Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2014, 16, 428.	1.6	46
24	Mining Cancer-Specific Disease Comorbidities from a Large Observational Health Database. <i>Cancer Informatics</i> , 2014, 13s1, CIN.S13893.	0.9	22
25	Molecular Insights into Systemic Lupus Erythematosus Pathogenesis. <i>Clinical Medicine Insights Pathology</i> , 2014, 7, CPath.S14814.	0.6	2
26	Cancer and scleroderma. <i>Current Opinion in Rheumatology</i> , 2015, 27, 563-570.	2.0	68
27	Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. <i>Journal of Dermatology</i> , 2015, 42, 524-527.	0.6	34
28	Early Stage Lung Cancer Detection in Systemic Sclerosis Does Not Portend Survival Benefit: A Cross Sectional Study. <i>PLoS ONE</i> , 2015, 10, e0117829.	1.1	13
29	Ribosomopathies: Global process, tissue specific defects. <i>Rare Diseases (Austin, Tex)</i> , 2015, 3, e1025185.	1.8	89
30	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , 2015, 348, 74-80.	6.0	1,735
31	The Pathogenesis of Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 367-382.	0.8	96
33	Drug-Associated Dermatomyositis Following Ipilimumab Therapy. <i>JAMA Dermatology</i> , 2015, 151, 195.	2.0	144
34	Reply. <i>Arthritis Care and Research</i> , 2015, 67, 452-453.	1.5	0
35	A Perspective on Cancer as an Abortive Autoimmune Response to Altered-Self. <i>Cancer Research</i> , 2015, 75, 3-4.	0.4	19
36	Systemic sclerosis: Recent insights. <i>Joint Bone Spine</i> , 2015, 82, 148-153.	0.8	54
37	Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics. <i>Journal of Immunology</i> , 2015, 194, 2049-2056.	0.4	119
38	Anti-RNA Polymerase III Autoantibody-Positive Scleroderma as a Paraneoplastic Syndrome: Comment on the Article by Stojan et al. <i>Arthritis Care and Research</i> , 2015, 67, 453-453.	1.5	0
39	The role of the acquired immune response in systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 519-528.	2.8	38
40	Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire. <i>Current Opinion in Immunology</i> , 2015, 35, 89-97.	2.4	80

#	ARTICLE	IF	CITATIONS
41	Case 8-2015: A Man with Multiple Myeloma, Skin Tightness, Arthralgias, and Edema. <i>New England Journal of Medicine</i> , 2015, 372, 2465-2466.	13.9	0
42	Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer-Associated Scleroderma. <i>Arthritis and Rheumatology</i> , 2015, 67, 1053-1061.	2.9	93
43	Neoantigens in cancer immunotherapy. <i>Science</i> , 2015, 348, 69-74.	6.0	3,809
44	Recent Advances in the Genetics of Systemic Sclerosis: Toward Biological and Clinical Significance. <i>Current Rheumatology Reports</i> , 2015, 17, 21.	2.1	25
45	Perception of self: distinguishing autoimmunity from autoinflammation. <i>Nature Reviews Rheumatology</i> , 2015, 11, 483-492.	3.5	88
46	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15002.	18.1	587
47	Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. <i>Pathologie Et Biologie</i> , 2015, 63, 61-68.	2.2	23
48	Post-transplantation malignancies: here today, gone tomorrow?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 705-717.	12.5	53
49	The immunopathology of systemic sclerosis. <i>Seminars in Immunopathology</i> , 2015, 37, 439-441.	2.8	8
50	Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?. <i>BMJ, The</i> , 2015, 351, h5079.	3.0	52
51	Review: Cancer-Induced Autoimmunity in the Rheumatic Diseases. <i>Arthritis and Rheumatology</i> , 2015, 67, 317-326.	2.9	90
52	Expression of the Dermatomyositis Autoantigen Transcription Intermediary Factor 1 ^β in Regenerating Muscle. <i>Arthritis and Rheumatology</i> , 2015, 67, 266-272.	2.9	42
53	Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. <i>Mediators of Inflammation</i> , 2016, 2016, 1-17.	1.4	28
54	Autoimmune Myopathies: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2016, 7, 234.	2.2	20
55	Cancers Related to Immunodeficiencies: Update and Perspectives. <i>Frontiers in Immunology</i> , 2016, 7, 365.	2.2	137
57	Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. <i>PLoS Medicine</i> , 2016, 13, e1002194.	3.9	473
58	Update on rheumatic heart disease. <i>Current Opinion in Cardiology</i> , 2016, 31, 162-168.	0.8	20
59	Association of IgG4-Related Disease With History of Malignancy. <i>Arthritis and Rheumatology</i> , 2016, 68, 2283-2289.	2.9	90

#	ARTICLE	IF	CITATIONS
60	Endometriosis research using capture microdissection techniques: Progress and future applications. Biomedical Reports, 2016, 5, 531-540.	0.9	7
61	Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Human Gene Therapy Methods, 2016, 27, 238-250.	2.1	22
62	Paraneoplastic systemic sclerosis: About 3 cases and review of literature. Journal Des Maladies Vasculaires, 2016, 41, 365-370.	0.6	16
63	Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. Best Practice and Research in Clinical Rheumatology, 2016, 30, 53-62.	1.4	25
64	Evolutionary Principles and Host Defense. , 2016, , 225-239.		0
65	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016, 139, 2131-2135.	3.7	202
66	RNA Polymerase III Advances: Structural and tRNA Functional Views. Trends in Biochemical Sciences, 2016, 41, 546-559.	3.7	78
67	The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?. Immunotherapy, 2016, 8, 601-612.	1.0	8
68	Alterations in nuclear structure promote lupus autoimmunity in a mouse model. DMM Disease Models and Mechanisms, 2016, 9, 885-97.	1.2	9
69	Autoantibodies and Their Role in Scleroderma Clinical Care. Current Treatment Options in Rheumatology, 2016, 2, 239-251.	0.6	16
70	High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis. Tohoku Journal of Experimental Medicine, 2016, 239, 297-305.	0.5	36
71	A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma. British Journal of Cancer, 2016, 115, 1555-1564.	2.9	12
72	The Emerging Role of B Cells in Tumor Immunity. Cancer Research, 2016, 76, 5597-5601.	0.4	278
73	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nature Communications, 2016, 7, 12983.	5.8	123
74	Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7526-E7534.	3.3	75
75	Next generation sequencing identifies abnormal Y chromosome and candidate causal variants in premature ovarian failure patients. Genomics, 2016, 108, 209-215.	1.3	12
77	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects. Medicine (United States), 2016, 95, e4713.	0.4	48
78	Fresh Insights into Disease Etiology and the Role of Microbial Pathogens. Current Rheumatology Reports, 2016, 18, 1.	2.1	38

#	ARTICLE	IF	CITATIONS
79	Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 415-427.	1.6	23
80	Hypodontia, a prospective predictive marker for tumor?. <i>Oral Diseases</i> , 2016, 22, 265-273.	1.5	12
81	Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis. <i>Journal of Dermatology</i> , 2016, 43, 808-810.	0.6	10
82	Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 115-135.	1.3	12
83	Mitochondrial DNA heteroplasmy in human health and disease. <i>Biomedical Reports</i> , 2016, 4, 259-262.	0.9	51
84	Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2016, 18, 27.	1.6	16
86	Overlapping IgG4 Responses to Self- and Environmental Antigens in Endemic Pemphigus Foliaceus. <i>Journal of Immunology</i> , 2016, 196, 2041-2050.	0.4	26
87	Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients. <i>Autoimmunity Reviews</i> , 2016, 15, 477-483.	2.5	196
88	Autoantibodies in Systemic Sclerosis. , 2016, , 231-247.		0
89	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
90	Autoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases. <i>Annual Review of Immunology</i> , 2016, 34, 395-420.	9.5	49
91	Radiotherapy in patients with connective tissue diseases. <i>Lancet Oncology</i> , The, 2016, 17, e109-e117.	5.1	42
92	Polymorphisms of the centrosomal gene (<i>FGFR1OP</i>) and lung cancer risk: a meta-analysis of 14 463 cases and 44 188 controls. <i>Carcinogenesis</i> , 2016, 37, 280-289.	1.3	7
93	PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1145-1151.	0.5	33
94	Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 20-33.	2.9	97
95	A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 1-19.	2.9	286
96	A 66-Year-Old Woman With Hemoptysis. <i>Arthritis Care and Research</i> , 2017, 69, 439-448.	1.5	2
97	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	1.0	93

#	ARTICLE	IF	CITATIONS
98	Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. <i>Journal of Experimental Medicine</i> , 2017, 214, 1129-1151.	4.2	69
99	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
100	Brief Report: Anti-RNPA Antibodies As a Marker of Cancer-Associated Scleroderma. <i>Arthritis and Rheumatology</i> , 2017, 69, 1306-1312.	2.9	61
101	Autoantibodies: Opportunities for Early Cancer Detection. <i>Trends in Cancer</i> , 2017, 3, 198-213.	3.8	106
102	Can killers be saviors?. <i>Lupus</i> , 2017, 26, 903-908.	0.8	6
103	Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment. <i>Rheumatology International</i> , 2017, 37, 847-851.	1.5	6
104	Two Unusual Cases of Oral Lichen Planus Arising After Oral Squamous Cell Carcinoma: Can Oral Cancer Trigger Autoimmunity?. <i>International Journal of Surgical Pathology</i> , 2017, 25, 443-448.	0.4	2
105	Systemic sclerosis. <i>Lancet, The</i> , 2017, 390, 1685-1699.	6.3	1,423
106	Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments. <i>Current Osteoporosis Reports</i> , 2017, 15, 142-152.	1.5	86
107	DNA repair and systemic lupus erythematosus. <i>DNA Repair</i> , 2017, 56, 174-182.	1.3	24
108	A To-Do List at Diagnosis of Systemic Sclerosis with Positive Anti-RNA Polymerase III Antibodies. <i>Journal of Rheumatology</i> , 2017, 44, 550-552.	1.0	8
109	Universal attenuators and their interactions with feedback loops in gene regulatory networks. <i>Nucleic Acids Research</i> , 2017, 45, 7078-7093.	6.5	3
110	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. <i>Trends in Immunology</i> , 2017, 38, 577-593.	2.9	276
111	Auto-antibodies and cancer in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2017, 16, 883-884.	2.5	7
112	A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. <i>Genome Medicine</i> , 2017, 9, 27.	3.6	92
113	Les nouvelles myopathies inflammatoires. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 392-402.	0.0	2
114	Novel risk factors related to cancer in scleroderma. <i>Autoimmunity Reviews</i> , 2017, 16, 461-468.	2.5	51
115	Genoproteomics-assisted improvement of <i>Andrographis paniculata</i> : toward a promising molecular and conventional breeding platform for autogamous plants affecting the pharmaceutical industry. <i>Critical Reviews in Biotechnology</i> , 2017, 37, 803-816.	5.1	14

#	ARTICLE	IF	CITATIONS
116	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2017, 69, 1751-1763.	1.5	292
117	Danger signals: Chemotherapy enhancers?. <i>Immunological Reviews</i> , 2017, 280, 175-193.	2.8	50
118	The roles and applications of autoantibodies in progression, diagnosis, treatment and prognosis of human malignant tumours. <i>Autoimmunity Reviews</i> , 2017, 16, 1270-1281.	2.5	52
119	Systemic Sclerosis. , 2017, , 165-178.		0
120	Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?. <i>Endocrine</i> , 2017, 58, 176-183.	1.1	25
121	An update on biomarker discovery and use in systemic sclerosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 823-833.	1.5	17
122	Cancer and autoimmune diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 1049-1057.	2.5	134
123	Resistance to TGF β 2 suppression and improved anti-tumor responses in CD8+ T cells lacking PTPN22. <i>Nature Communications</i> , 2017, 8, 1343.	5.8	37
124	Multi-class computational evolution: development, benchmark evaluation and application to RNA-Seq biomarker discovery. <i>BioData Mining</i> , 2017, 10, 13.	2.2	10
125	Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. <i>Rheumatology</i> , 2017, 56, 317-318.	0.9	17
126	Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis. <i>Journal of Proteome Research</i> , 2017, 16, 355-365.	1.8	25
127	Macrophage NOS2 in Tumor Leukocytes. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 1023-1043.	2.5	17
128	Immune-Related Adverse Effects of Cancer Immunotherapyâ Implications for Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 65-78.	0.8	101
129	Is Tolerance Broken in Autoimmunity?. <i>Clinical Medicine Insights Pathology</i> , 2017, 10, 117955571771271.	0.6	2
130	Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 992.	2.2	74
131	Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure. <i>Case Reports in Immunology</i> , 2017, 2017, 1-3.	0.2	6
132	Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature. <i>Case Reports in Rheumatology</i> , 2017, 2017, 1-12.	0.2	12
133	Cancer Risk in Rheumatic Diseases. , 2017, , 547-559.		0

#	ARTICLE	IF	CITATIONS
134	Mechanistic and clinical insights at the scleroderma-cancer interface. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 153-159.	1.0	21
135	Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting. <i>Journal of Nippon Medical School</i> , 2017, 84, 56-63.	0.3	46
136	Small Cell Lung Cancer in a 20-year-old Non-Smoking Man with Systemic Sclerosis. <i>Internal Medicine</i> , 2017, 56, 1549-1552.	0.3	0
137	Musculoskeletal Syndromes in Malignancy. , 2017, , 2048-2065.e6.		2
138	Regulation of autoimmune and anti-tumour T cell responses by PTPN22. <i>Immunology</i> , 2018, 154, 377-382.	2.0	33
139	Evidence supports blind screening for internal malignancy in dermatomyositis. <i>Medicine (United Kingdom)</i> 2018; 97(10):e0174.	0.4	74
140	Moments of Wonder. <i>American Journal of Medicine</i> , 2018, 131, 852-853.	0.6	2
141	Autoantibodies in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 290-302.	3.5	248
142	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-212999.	0.5	60
143	Anti-HMGCR Myopathy. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 11-20.	1.1	101
144	Molecular hypotheses to explain the shared pathways and underlying pathobiological causes in catatonia and in catatonic presentations in neuropsychiatric disorders. <i>Medical Hypotheses</i> , 2018, 113, 54-64.	0.8	12
145	Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. <i>Rheumatology</i> , 2018, 57, 388-396.	0.9	81
146	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2018, 45, 835-840.	1.0	23
147	Scleroderma renal crisis and cancer. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 261-262.	0.2	1
148	FOXOs in cancer immunity: Knowns and unknowns. <i>Seminars in Cancer Biology</i> , 2018, 50, 53-64.	4.3	56
149	Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. <i>Acta Neuropathologica</i> , 2018, 135, 569-579.	3.9	73
150	Neurological syndromes driven by postinfectious processes or unrecognized persistent infections. <i>Current Opinion in Neurology</i> , 2018, 31, 318-324.	1.8	15
151	Phage Immunoprecipitation Sequencing of Autoantigens in Autoimmune Retinopathy. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 417-424.	1.0	5

#	ARTICLE	IF	CITATIONS
152	Inflammatory myopathies: A new landscape. <i>Joint Bone Spine</i> , 2018, 85, 23-33.	0.8	31
154	Anti-NXP2-antibody-positive immune-mediated necrotizing myopathy associated with acute myeloid leukemia. <i>Medicine (United States)</i> , 2018, 97, e11501.	0.4	3
156	Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 201-213.	1.0	11
157	Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 223-240.	1.4	75
158	The diagnostic work-up of cancer-associated myositis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 630-636.	2.0	37
159	Association between loss of heterozygosity of chromosome 16q and survival in Wilms's tumor: A meta-analysis. <i>Pathology Research and Practice</i> , 2018, 214, 1772-1777.	1.0	5
160	An update on autoantibodies in scleroderma. <i>Current Opinion in Rheumatology</i> , 2018, 30, 548-553.	2.0	21
161	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018, 20, 187.	1.6	33
162	Therapeutic Applications of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1089, 73-85.	0.8	17
163	Reply. <i>Annals of Thoracic Surgery</i> , 2018, 106, 935-936.	0.7	0
164	Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 214-220.	1.0	9
165	Mycobacterium tuberculosis peptide E7/HLA-DRB1 tetramers with different HLA-DR alleles bound CD4+ T cells might share identical CDR3 region. <i>Scientific Reports</i> , 2018, 8, 9903.	1.6	0
166	Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature. <i>Rheumatology International</i> , 2018, 38, 1743-1749.	1.5	8
167	Mutated cancer autoantigen implicated cause of paraneoplastic myasthenia gravis. <i>Muscle and Nerve</i> , 2018, 58, 600-604.	1.0	10
168	Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?. <i>Journal of Rheumatology</i> , 2018, 45, 731-732.	1.0	3
169	The microbiome in autoimmune diseases. <i>Clinical and Experimental Immunology</i> , 2018, 195, 74-85.	1.1	311
171	Microsatellite Analysis of Recurrent Lesions Confirms Merit of Anatomical Liver Resection for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2019, 39, 4315-4324.	0.5	2
172	Phosphodiesterase 10A IgG. <i>Neurology</i> , 2019, 93, e815-e822.	1.5	52

#	ARTICLE	IF	CITATIONS
173	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 2100-2111.	2.9	202
174	Comorbidity burden in systemic sclerosis: beyond disease-specific complications. <i>Rheumatology International</i> , 2019, 39, 1507-1517.	1.5	19
175	Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1865-1878.	1.4	49
177	Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. <i>Neuromuscular Disorders</i> , 2019, 29, 819-825.	0.3	12
178	Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. <i>Frontiers in Immunology</i> , 2018, 9, 3112.	2.2	62
179	Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. <i>Scientific Reports</i> , 2019, 9, 355.	1.6	13
180	Autoreactive T-Lymphocytes in Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1198.	2.2	48
181	Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies. <i>Frontiers in Neurology</i> , 2019, 10, 438.	1.1	32
183	Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 1014.	2.2	74
184	Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three Aâ€™s: Abundance, Activation and Antigen-Delivery. <i>Cancers</i> , 2019, 11, 670.	1.7	15
185	Cancer and Autoimmune Diseases. , 2019, , 453-465.		1
186	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 811-827.	1.4	27
188	Protective Effect Against Cancer of Antibodies to the Large Subunits of Both <i>RNA Polymerase I</i> and <i>RNA Polymerase III</i> in Scleroderma. <i>Arthritis and Rheumatology</i> , 2019, 71, 1571-1579.	2.9	34
189	The IgG2 Isotype of Anti-Transcription Intermediary Factor 1 Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1360-1370.	2.9	33
190	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 535-548.	12.5	186
191	Cancer Immunoediting by Innate Lymphoid Cells. <i>Trends in Immunology</i> , 2019, 40, 415-430.	2.9	35
192	Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1449-1451.	0.6	21
193	A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1451-1453.	0.6	21

#	ARTICLE	IF	CITATIONS
194	Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. <i>Oncolimmunology</i> , 2019, 8, e1588084.	2.1	23
195	Parathyroid adenoma with prominent lymphocytic infiltrate having histological features highly suggestive of IgG4-related disease: a case report and literature review. <i>Endocrine Journal</i> , 2019, 66, 379-385.	0.7	2
196	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. <i>Lancet Rheumatology</i> , The, 2019, 1, e257-e264.	2.2	17
197	Cancer and Idiopathic Inflammatory Myositis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 231-241.	0.6	2
198	The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 643-649.	2.0	32
199	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1 ^β Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. <i>Internal Medicine</i> , 2019, 58, 427-431.	0.3	3
200	Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 36-42.	2.5	24
201	Antinuclear Antibodies in Systemic Sclerosis: an Update. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 58, 40-51.	2.9	87
202	Muscle transcriptome signature and gene regulatory network analysis in two divergent lines of a hilly bovine species <i>Mithun</i> (<i>Bos frontalis</i>). <i>Genomics</i> , 2020, 112, 252-262.	1.3	12
203	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.3	148
204	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. <i>Seminars in Cancer Biology</i> , 2020, 64, 93-101.	4.3	135
205	Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 103-129.	1.0	24
206	Systemic Sclerosis (Scleroderma). , 2020, , 575-605.		0
207	Autoimmune disease in CMML-the chicken or the egg?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101136.	0.7	16
208	Aetiology and pathogenesis of paraneoplastic autoimmune disorders. <i>Autoimmunity Reviews</i> , 2020, 19, 102422.	2.5	18
209	The Autoimmune Myopathies. , 2020, , 703-713.		0
210	An autoantibody against a 48-Kd fragment of human DNA-topoisomerase I in breast cancer: Implication for diagnosis and prognosis, and antibody-dependent cellular cytotoxicity in vitro. <i>Cellular Immunology</i> , 2020, 347, 104007.	1.4	7
212	Systemic sclerosis: Update for oral health care providers. <i>Special Care in Dentistry</i> , 2020, 40, 418-430.	0.4	5

#	ARTICLE	IF	CITATIONS
213	Breaking β^2 Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapyâ€“Induced Diabetes Mellitus. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa114.	0.1	3
214	<p>Association of Silicone Breast Implants, Breast Cancer and Anti-RNA Polymerase III Autoantibodies in Systemic Sclerosis: Case-Based Review</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 207-213.	0.8	6
215	Establishment and application of a novel method based on single nucleotide polymorphism analysis for detecting β^2 -globin gene cluster deletions. <i>Scientific Reports</i> , 2020, 10, 18298.	1.6	3
216	Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 3388.	1.0	24
217	Recurrent Pulmonary Fibrosis in a Lung Allograft Secondary to <i>De Novo</i> Antisynthetase Syndrome. <i>Annals of the American Thoracic Society</i> , 2020, 17, 901-904.	1.5	5
218	Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa150.	0.1	4
219	Expression of the Autoantigen Topoisomeraseâ€“1 is Enriched in the Lung Tissues of Patients With Autoimmune Interstitial Lung Disease: A Case Control Study. <i>ACR Open Rheumatology</i> , 2020, 2, 657-661.	0.9	4
220	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. <i>Frontiers in Oncology</i> , 2020, 10, 604685.	1.3	11
221	Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1105-1113.	1.3	7
222	Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2020, 11, 991.	2.2	34
223	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. <i>Clinical Immunology</i> , 2020, 213, 108377.	1.4	44
224	The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases. <i>Cellular and Molecular Immunology</i> , 2020, 17, 335-346.	4.8	23
225	Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma. <i>Arthritis and Rheumatology</i> , 2020, 72, 1375-1384.	2.9	12
226	RNA polymerase III transcription as a disease factor. <i>Genes and Development</i> , 2020, 34, 865-882.	2.7	55
227	Cancer and Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 551-564.	0.8	14
228	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
229	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). <i>Cancer Letters</i> , 2020, 490, 12-19.	3.2	10
230	The relationships between cancer and autoimmune rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101472.	1.4	30

#	ARTICLE	IF	CITATIONS
231	Estimating growth patterns and driver effects in tumor evolution from individual samples. <i>Nature Communications</i> , 2020, 11, 732.	5.8	18
233	Autoantibody Biomarkers in Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1382.	1.8	22
234	Hematological malignancies in connective tissue diseases. <i>Lupus</i> , 2020, 29, 225-235.	0.8	6
235	Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3069.	1.8	14
236	Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. <i>Seminars in Immunology</i> , 2020, 47, 101394.	2.7	8
237	Occurrence of Immunoglobulin G4-related Disease during Chemotherapy for Advanced Breast Cancer. <i>Internal Medicine</i> , 2020, 59, 1649-1654.	0.3	1
238	Biphasic Temporal Relationship between Cancers and Systemic Sclerosis: A Clinical Series from Montpellier University Hospital and Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 853.	1.0	15
239	Advances at the interface of cancer and systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 50-57.	1.0	4
240	Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports. <i>Rheumatology</i> , 2021, 60, e47-e49.	0.9	2
242	Enhanced humoral immunity in breast cancer patients with high serum concentration of anti-HER2 autoantibody. <i>Cancer Medicine</i> , 2021, 10, 1418-1430.	1.3	9
243	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	0.9	34
244	Clonal expansion in non-cancer tissues. <i>Nature Reviews Cancer</i> , 2021, 21, 239-256.	12.8	133
245	TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1 ^β positive cancer-associated dermatomyositis. <i>Rheumatology</i> , 2021, 60, 5863-5867.	0.9	10
247	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.3	14
248	Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 50.	2.3	6
249	The Autoantigen Repertoire and the Microbial RNP World. <i>Trends in Molecular Medicine</i> , 2021, 27, 422-435.	3.5	4
250	Gut Microbiota and Inflammatory Disorders. <i>Current Drug Targets</i> , 2022, 23, 156-169.	1.0	2
251	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7

#	ARTICLE	IF	CITATIONS
252	Autoimmune Responses in Oncology: Causes and Significance. International Journal of Molecular Sciences, 2021, 22, 8030.	1.8	12
253	Insights Into Systemic Sclerosis from Gene Expression Profiling. Current Treatment Options in Rheumatology, 2021, 7, 208-221.	0.6	0
254	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. Journal of Autoimmunity, 2021, 122, 102680.	3.0	14
255	An Intradermal Spindle Cell Lipoma on the Plantar Hallux in a Patient With Scleroderma and Ehlers-Danlos Syndrome: A Case Report. Journal of Foot and Ankle Surgery, 2022, 61, 199-201.	0.5	0
256	Insights into origins and specificities of autoantibodies in systemic sclerosis. Current Opinion in Rheumatology, 2021, 33, 486-494.	2.0	7
257	Current Concepts on the Pathogenesis of Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2023, 64, 262-283.	2.9	45
258	Autoimmunity and cancer. Autoimmunity Reviews, 2021, 20, 102882.	2.5	13
260	Network Analysis of Human Disease Comorbidity Patterns Based on Large-Scale Data Mining. Lecture Notes in Computer Science, 2014, , 243-254.	1.0	7
261	Inflammation and Immunity. , 2017, , 161-195.		2
263	Mitochondrial Heteroplasmy. Advances in Experimental Medicine and Biology, 2017, 982, 577-594.	0.8	40
265	Precision medicine: discovering clinically relevant and mechanistically anchored disease subgroups at scale. Journal of Clinical Investigation, 2019, 129, 944-945.	3.9	16
266	Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases. Breathe, 2020, 16, 200203.	0.6	8
267	Active Center Control of Termination by RNA Polymerase III and tRNA Gene Transcription Levels In Vivo. PLoS Genetics, 2016, 12, e1006253.	1.5	15
268	An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Medica, 2021, 63, 249-260.	0.2	17
269	Clinical and Molecular Features of Anti-CENP-B Autoantibodies. Journal of Molecular Pathology, 2021, 2, 281-295.	0.5	7
270	Cancer Risk in Rheumatic Diseases. , 2013, , 515-527.		0
271	Tweeting Biology for Better Data and Better Connections. Journal of Nuclear Medicine & Radiation Therapy, 2014, 06, .	0.2	0
276	Cancer in Systemic Sclerosis. , 2017, , 525-532.		0

#	ARTICLE	IF	CITATIONS
277	7. Practical Use of Autoantibody Testing in Connective Tissue Diseases. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 470-475.	0.0	0
279	Immune-Mediated Necrotizing Myopathy (IMNM). , 2020, , 225-235.		0
280	Modern diagnostic methods of paraneoplastic pemphigus. Vestnik Dermatologii I Venerologii, 2019, 95, 7-16.	0.2	0
281	THE RELATIONSHIP BETWEEN OF CANCERS AND RHEUMATIC DISEASES. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 198-206.	0.2	0
282	Scleroderma as a paraneoplastic syndrome and tumors associated with scleroderma. Klinicist, 2020, 14, 55-61.	0.1	0
283	Lung Cancer Survival in Patients With Autoimmune Disease. JAMA Network Open, 2020, 3, e2029917.	2.8	16
285	Triggers of inflammatory myopathy: insights into pathogenesis. Discovery Medicine, 2018, 25, 75-83.	0.5	22
286	Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 71-74.	0.4	10
287	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Annals of Translational Medicine, 2020, 8, 1415.	0.7	0
289	Computational cancer neoantigen prediction: current status and recent advances. Immuno-Oncology Technology, 2021, 12, 100052.	0.2	14
290	Increased malignancies in systemic sclerosis. International Journal of Rheumatic Diseases, 2022, 25, 90-92.	0.9	3
291	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Annals of Translational Medicine, 2020, 8, 1415-1415.	0.7	2
292	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
293	Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. Journal of Clinical Investigation, 2022, 132, .	3.9	26
294	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics, 2022, 19, 848-863.	2.1	10
296	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
297	Cancer-associated systemic sclerosis in a Canadian cohort: beyond strengths and weaknesses of epidemiological studies. Rheumatology, 2022, , .	0.9	0
298	Keep a Little Fire Burningâ€”The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity. International Journal of Molecular Sciences, 2022, 23, 1289.	1.8	2

#	ARTICLE	IF	CITATIONS
299	The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, 14.	1.6	24
300	Association of immunoglobulin G4-related disease with a family history of malignancy: A retrospective study of 168 cases. <i>Rheumatology & Autoimmunity</i> , 2021, 1, 73-82.	0.3	2
301	Scleroderma Renal Crisis Associated With Microangiopathic Hemolytic Anemia in a Patient With Seronegative Scleroderma and Monoclonal Gammopathy. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962210745.	0.3	3
302	B cell receptor signaling strength modulates cancer immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
303	Comment on: Favourable complete remission of anti-OJ antibody-positive myositis after lung cancer resection: Reply. <i>Rheumatology</i> , 2022, , .	0.9	0
304	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 358-377.	2.9	8
305	The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. <i>Cancer Communications</i> , 2022, 42, 435-446.	3.7	22
306	Advances in pharmacotherapy for acute and recurrent pericarditis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 681-691.	0.9	6
307	Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. <i>Nature Reviews Cancer</i> , 2022, 22, 414-430.	12.8	109
308	Introduction on autoimmunity and associated conditions. , 2022, , 1-13.		0
309	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
310	Current and Developing Liquid Biopsy Techniques for Breast Cancer. <i>Cancers</i> , 2022, 14, 2052.	1.7	19
311	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	1.1	6
312	Paraneoplastic neurological syndrome: growing spectrum and relevance. <i>Neurological Sciences</i> , 2022, 43, 3583-3594.	0.9	4
313	Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 330-341.	2.9	8
314	The Genetics of Autoimmune Myositis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
315	PTPN22: structure, function, and developments in inhibitor discovery with applications for immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 825-837.	2.5	3
316	Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 412-430.	2.9	23

#	ARTICLE	IF	CITATIONS
317	DNA from macrophages induces fibrosis and vasculopathy through POLR3A/STING/type I interferon axis in systemic sclerosis. <i>Rheumatology</i> , 2023, 62, 934-945.	0.9	3
318	Coexistence of Multiple Pulmonary Sclerosing Pneumocytoma and Scleroderma in Rheumatoid Arthritis Overlap Syndrome: A Case Report. , 2022, 23, 302-305.		0
319	Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	59
320	Stiff person syndrome spectrum disorders; more than meets the eye. <i>Journal of Neuroimmunology</i> , 2022, 369, 577915.	1.1	23
321	Genomic instability in early systemic sclerosis. <i>Journal of Autoimmunity</i> , 2022, 131, 102847.	3.0	9
322	The role of ROH in the etiopathogenesis of complex diseases. <i>South of Russia: Ecology, Development</i> , 2022, 17, 130-139.	0.1	0
323	Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population. <i>Arthritis and Rheumatology</i> , 2023, 75, 620-629.	2.9	7
324	Cellular and molecular diversity in rheumatic autoimmune diseases. <i>Seminars in Immunology</i> , 2022, , 101648.	2.7	0
325	Concurrence of IgG4-related disease and Kimura disease with pulmonary embolism and lung cancer: a case report. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	2
326	Peptide Microarrays for Studying Autoantibodies in Neurological Disease. <i>Methods in Molecular Biology</i> , 2023, , 17-25.	0.4	5
327	Systemic Sclerosis Association with Malignancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 398-416.	2.9	7
328	CD8+ T Cell Phenotype and Function in Childhood and Adult-Onset Connective Tissue Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11431.	1.8	5
329	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	3.5	37
330	Challenges in neoantigen-directed therapeutics. <i>Cancer Cell</i> , 2023, 41, 15-40.	7.7	27
331	Four Cases of RNA Polymerase Antibody-Positive Systemic Scleroderma with Malignant Tumor in Our Hospital. <i>Nishinon Journal of Dermatology</i> , 2022, 84, 429-433.	0.0	0
332	Chemotherapy-Induced, Broadly Reactive Autoantibodies in a Colon Cancer Patient. <i>Cureus</i> , 2022, , .	0.2	2
333	RNA polymerase III transcription and cancer: A tale of two RPC7 subunits. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
334	Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19. , 2023, , 351-368.		0

#	ARTICLE	IF	CITATIONS
335	Autoantibodies as Diagnostic Cancer Biomarkers. , 2023, , 1-34.		0
336	Preventative Care in Scleroderma. Rheumatic Disease Clinics of North America, 2023, 49, 411-423.	0.8	0
337	Clinical and immunological features of patients with cancer-associated systemic sclerosis: An observational study. Joint Bone Spine, 2023, 90, 105555.	0.8	4
338	A combination of autoantibodies predicts the fate of cancer-associated dermatomyositis. Arthritis and Rheumatology, 0, , .	2.9	0
339	Prostaglandins limit nuclear actin to control nucleolar function during oogenesis. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	1
340	Paraneoplastic Myopathy. , 2023, , 141-147.		0
341	Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature. Acta Clinica Belgica, 2023, 78, 410-417.	0.5	1
342	Malignancies in systemic rheumatic diseases: A mini review. Frontiers in Immunology, 0, 14, .	2.2	0